Teva’s Copaxone Maintains a Dominant Presence in the MS Treatment Algorithm among Both Newly Diagnosed and Recently Treated Patients

Decision Resources Unveils New Online Platform for Its Treatment Algorithms Service

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that among recently treated multiple sclerosis (MS) patients in the fourth quarter of 2010, Teva’s Copaxone garnered the highest patient share among key individual MS therapies, while the interferon-beta products as a class captured the largest patient share. Copaxone was also the preferred therapy among newly diagnosed MS patients in both the first and second lines of therapy.

“Meanwhile, Tysabri’s strong efficacy and excellent tolerability, coupled with the continued need for highly effective treatments, render it an important option for treatment-refractory patients or those with high disease activity.”

According to Treatment Algorithms in Multiple Sclerosis, Biogen Idec/Elan’s Tysabri saw little use as a first-line therapy among newly diagnosed patients, consistent with its labeling, but experienced a considerable increase in patient share as a second-line therapy. In addition, Tysabri received nearly a 10 percent patient share among recently treated patients in the last quarter of 2010.

“Copaxone’s dominant presence in early lines of MS treatment reflects in part its comparable efficacy to and its tolerability advantage over the interferon-beta products. Moreover, patients who fail an interferon-beta product in the first line may move to Copaxone second-line because of its alternative mechanism of action,” said Decision Resources Analyst Georgiana Kuhlmann, S.M. “Meanwhile, Tysabri’s strong efficacy and excellent tolerability, coupled with the continued need for highly effective treatments, render it an important option for treatment-refractory patients or those with high disease activity.”

Enhanced Service and Platform Now Available

The analysis is part of Decision Resources’ enhanced Treatment Algorithms series, which features a new online platform. Interactive, user-friendly and with more graphical data views, the new platform enables users to easily toggle between diseases and time cohorts, which ultimately allows for more in-depth analysis on each line of therapy. Treatment Algorithms analysis is now updated quarterly to provide ongoing trending of product utilization by line of therapy and new therapy initiations. Through examination of U.S. patient-level claims data, Decision Resources’ Treatment Algorithms series provides exceptional insight into physicians’ prescribing trends and the factors that drive therapy choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.